Tehran University of Medical Sciences Acta Medica Iranica 0044-6025 57 8 2020 02 15 472 477 EN Sahar Tavakolian Medical Genetics Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.AND Department of Biology, University of Sistan and Balouchestan, Zahedan, Iran. Matineh Barati Bagherabad Medical Genetics Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. AND 3 Department of Biology, Ashkezar Branch, Islamic Azad University, Ashkezar, Yazd, Iran. Dor Mohammad Kordi-Tamandani Department of Biology, University of Sistan and Balouchestan, Zahedan, Iran. AND Genetics and Biotechnology Research Institute, University of Sistan and Baluchestan, Zahedan, Iran. Mohammad Reza Abbaszadegan Medical Genetics Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. AND Department of Medical Genetics, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. AND Immunology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran . Mohammad Amin Kerachian Medical Genetics Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. AND Department of Medical Genetics, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. AND Cancer Genetics Research Unit, Reza Radiotherapy and Oncology Center, Mashhad, Iran. 2018 12 22 2019 10 31 Aberrant promoter methylation of CpG islands of tumor-suppressor genes has been recognized as one of the important tumor markers for cancer detection. The aim of this study was to investigate the promoter methylation status of protocadherin 10 (PCDH10), a tumor suppressor gene, in Iranian colorectal cancer (CRC) patients. Cancerous and the adjacent normal tissues obtained from 38 CRC patients were used to assess the methylation status of PCDH10 with Methylation Specific PCR, in addition, to study the expression level of this gene by quantitative PCR. The relationship between hypermethylation and the demographic characteristics of these patients was analyzed. The promoter methylation level of PCDH10 was statistically different between tumoral and normal tissues in CRC patients. Twenty-seven out of 38 patients showed hypermethylation with a sensitivity of 73% and a specificity of 97%. PCDH10 expression decreased in 15 cases (46%) as 16 cases (50 %) showed overexpression and 1 case (4%) had no changes. Not a significant association was reported between PCDH10 hypermethylation and the clinicopathological characteristics (P>0.05). Our results indicated that PCDH10 methylation has a critical function in CRC, with a nearly elevated sensitivity and a high specificity in the Iranian population, qualify it as a potential candidate biomarker. https://acta.tums.ac.ir/index.php/acta/article/view/7640 https://acta.tums.ac.ir/index.php/acta/article/download/7640/5300